Lifecore Biomedical, Inc.
LFCR
$4.93
-$0.05-1.00%
NASDAQ
| 03/31/2026 | 09/30/2025 | 05/25/2025 | 05/25/2025 | 02/23/2025 | |
|---|---|---|---|---|---|
| Revenue | -34.02% | 25.92% | -3.81% | -3.81% | -1.54% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -34.02% | 25.92% | -3.81% | -3.81% | -1.54% |
| Cost of Revenue | -25.99% | 20.71% | 8.96% | 8.96% | 6.30% |
| Gross Profit | -54.68% | 44.63% | -19.05% | -19.05% | -17.23% |
| SG&A Expenses | -37.41% | -27.59% | -14.69% | -14.69% | 2.49% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -29.86% | 1.15% | 0.73% | 0.73% | 4.52% |
| Operating Income | -33.97% | 66.24% | -36.77% | -36.77% | -1,749.19% |
| Income Before Tax | -1.08% | 40.58% | 84.40% | 84.40% | -198.50% |
| Income Tax Expenses | 637.50% | 1,432.00% | 157.89% | 157.89% | -103.69% |
| Earnings from Continuing Operations | -1.43% | 38.44% | 83.81% | 83.81% | -199.89% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -1.43% | 38.44% | 83.81% | 83.81% | -194.48% |
| EBIT | -33.97% | 66.24% | -36.77% | -36.77% | -1,749.19% |
| EBITDA | -251.15% | 84.68% | -27.06% | -27.06% | -111.53% |
| EPS Basic | 9.42% | 44.52% | 76.15% | 76.15% | -191.55% |
| Normalized Basic EPS | -63.77% | 42.07% | 37.90% | 37.90% | -142.00% |
| EPS Diluted | 9.53% | 44.94% | 76.15% | 76.15% | -211.08% |
| Normalized Diluted EPS | -63.77% | 42.07% | 37.90% | 37.90% | -150.43% |
| Average Basic Shares Outstanding | 1.23% | 21.22% | 21.15% | 21.15% | 21.43% |
| Average Diluted Shares Outstanding | 1.23% | 21.22% | 21.15% | 21.15% | 1.12% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |